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Summary
Background:Cell-size-control systems, coupled with apopto-
tic- and cell-proliferation-regulatory mechanisms, determine
the overall dimensions of organs and organisms, and their dys-
regulation can lead to tumor formation. The interrelationship
between cell-growth-regulatory mechanisms and apoptosis
during normal development and cancer is not understood.
The TRK-fused gene (TFG) promotes tumorigenesis when
present in chromosomal rearrangements from various
human-cancer types by unknown mechanisms. Apaf1/CED-4
is essential for apoptosis but has not been shown to function
in cell-growth control.
Results: We found that loss of TFG-1, the TFG ortholog in
Caenorhabditis elegans, results in supernumerary apoptotic
corpses, whereas its overexpression is sufficient to inhibit de-
velopmentally programmed cell death. TFG-1 is also required
for cells and nuclei to grow to normal size. Furthermore, we
found that CED-4 is required for cell-growth inhibition in ani-
mals lacking TFG-1. However, caspases, the downstream
effectors of CED-4-mediated apoptosis, are not required in
TFG-1- or CED-4-regulated cell-size control. CED-4 acts to
inhibit cell growth by antagonizing the effects of other con-
served cell-size-regulating proteins, including cAMP response
element binding (CREB) protein, translation-initiation factor
eIF2B, and the nucleolar p53-interacting protein nucleostemin.
Conclusions: These findings show that TFG-1 suppresses
apoptosis and is essential for normal cell-size control, sug-
gesting that abnormalities in the cell-growth-promoting and
apoptosis-inhibiting functions of TFG might be responsible
for its action in tumorigenesis. Also, they reveal that CED-4
plays a pivotal role in activating apoptosis and restricting cell
and nuclear size, thereby determining the appropriate overall
size of an animal. Thus, these findings reveal links between
the control mechanisms for apoptosis and cell growth.
Introduction
Cells actively modulate growth parameters to achieve repro-
ducible dimensions appropriate to their functions. Cell-size-
control systems, coupled with regulatory mechanisms for
apoptotic cell death and cell proliferation, determine the over-
all dimensions of organs and organisms, and dysregulation of
these processes can lead to cancer. Apoptosis and cell size
are controlled by largely distinct molecular-regulatory events.
*Correspondence: rothman@lifesci.ucsb.eduThe pathways regulating apoptosis are highly conserved
among animals. The core apoptotic-regulatory pathway in
C. elegans consists of four proteins (CED-3, CED-4, CED-9,
and EGL-1) that are critical for the switch between cell survival
and apoptosis [1]. CED-3, a member of the caspase family of
cysteine proteases and the main executor of apoptosis, is
triggered to undergo autoproteolytic activation into its proa-
poptotic form by CED-4, an ortholog of mammalian Apaf-1.
CED-9, the worm equivalent of mammalian proto-oncoprotein
Bcl-2, promotes cell survival by binding to CED-4 and prevent-
ing it from activating CED-3. In cells fated to undergo apopto-
sis, the anti-apoptotic activity of CED-9 is blocked by EGL-1,
a BH3-only-domain protein.
In contrast to apoptosis, several independent mechanisms
appear to regulate cell size. The best-understood mechanism
controlling cell and body size in C. elegans is the Sma/Mab
pathway, involving members of the TGF-b superfamily and
their transducers [2]. Smads encoded by sma-2, sma-3, and
sma-4 transduce TGF-b signals into the nucleus and regulate
cell and body size through transcriptional regulation of lon-1
and other downstream factors. The Sma/Mab pathway is
negatively regulated by LON-2, a member of the glypican
family [3]. Epistasis studies have shown that LON-2 functions
upstream of the Sma/Mab pathway, as mutations in lon-2
produce long animals only when the TGF-b ligand DBL-1 and
the TGF-b receptor SMA-6 are intact [3]. A number of other
cell-size-regulatory mechanisms exist, including the insulin/
insulin-like growth factor (IGF)- and target of Rapamycin
(TOR)-signaling pathways [4]; however, their roles in cell-size
regulation in C. elegans are less defined.
Though the control of cell growth and apoptosis must be
coordinated, little is known about how this is achieved. We
have found that the essential apoptotic regulator, ced-4, and
the C. elegans ortholog of the human TFG proto-oncogene
participate in both cell-size control and apoptosis, suggesting
that they link these two processes. The human TFG gene was
identified from chromosomal rearrangements in a variety of
malignant tumor types, including papillary thyroid carcinomas,
anaplastic large cell lymphomas, and extraskeletal myxoid
chondrosarcomas [5–8] (Figure 1A). All resulting protein
chimeras contain an in-frame fusion of TFG at the amino-termi-
nus, and some have been shown to possess oncogenic activ-
ity [5, 7, 9]. The TFG portion of the oncogenic-fusion form is es-
sential for this transforming activity, as well as for interactions
with other proteins [10–13]. TFG is upregulated in response to
TALL-1 [14], a member of the tumor-necrosis-factor family
implicated in B cell proliferation and autoimmunity. TFG was
recently reported to interact with PTEN [15], a key tumor sup-
pressor that modulates cell growth, division, and death. These
findings raise the possibility that TFG might contribute to
cancer by regulating such cellular activities.
We report here that the single TFG ortholog in C. elegans,
tfg-1 [16] (Figure 1A), both suppresses apoptotic cell death
and activates cell and nuclear growth by a pathway that is
apparently independent of TGF-b- and insulin-signaling path-
ways. The reduced cell and nuclear size seen in the absence
of TFG requires CED-4 function, implicating CED-4 in cell
growth inhibition in addition to its proapoptotic action.
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(A) Schematic representation of human and C. elegans TFG orthologs and human TFG protein chimeras in various cancers. Red box, SH2 binding motif; cc,
coiled-coil domain; black box, SH3 binding motif.
(B) Histogram of cell-corpse numbers in comma-stage embryos of the given genotype.
(C and D) Histogram of cell-corpse numbers in comma-stage embryos without heat shock (black bars) and with heat shock (yellow bars). Heat shock leads to
a reduced number of cell corpses, specifically in hs-tfg-1 transgenic animals (C) but not in control hs-lacZ animals (D).Moreover, we found that three other proteins whose functions
are required for normal cell and body size are also antagonized
by CED-4, suggesting that CED-4 performs a general role in re-
striction of cell growth and body size. Thus, CED-4 might pro-
vide a mechanism for coordinating the processes of cell death
and cell growth/cell-size control.
Results
TFG-1 Regulates Apoptotic Cell Death
To evaluate the tfg-1 gene’s possible role in growth, prolifera-
tion, and apoptosis, we investigated its function in C. elegans.
We found that inactivation of tfg-1 by RNAi results in a signifi-
cant increase in the number of apoptotic corpses during em-
bryogenesis (Figure 1B). At the ‘‘comma’’ stage of embryogen-
esis, when much programmed cell death occurs, tfg-1(RNAi)
embryos contain an average of 12.6 6 2.8 corpses, signifi-
cantly higher than the number in control wild-type embryos
(8.5 6 2.7 corpses; Wilcoxon rank sum, p = 2.98 3 1026). A
similar elevation in cell-corpse number is also seen in
a cell-corpse-engulfment-defective ced-1(e1735) mutant
(Figure S1A, available online). This elevated cell death was
blocked by mutations in the core cell-death pathway (data
not shown), indicating that most cell death in tfg-1(RNAi)
worms relies on the canonical CED-3, CED-4-dependent cell-
death pathway. However, later in development, some cells
undergo CED-3-independent death in tfg-1(RNAi) animals
(Table S1). Such CED-4-dependent, CED-3-independentapoptosis has also been reported with the ICD-1 cell-death
suppressor [17].
Localization of TFG-1 is consistent with a role in apoptosis:
immunoreactive TFG-1 is detectable as early as the two cell
stage of embryogenesis, and its expression continues
throughout embryogenesis (e.g., Figure 2). Closer examination
of the subcellular localization of TFG-1 revealed a punctuated
staining pattern in the cytoplasm, which partially colocalizes
with mitochondrial COX1 (Figures 2D–2F). Given that mito-
chondria are key sites for apoptotic regulators [1], the partial
mitochondrial localization of TFG-1 and the tfg-1(RNAi) pheno-
type are suggestive of a possible anti-apoptotic action in this
organelle.
The elevation in cell-corpse number in tfg-1(RNAi) animals
results from either inappropriate cell death or reduced engulf-
ment of cell corpses. To further assess the role of tfg-1 in
apoptotic regulation, we asked whether its overexpression is
sufficient to suppress developmentally programmed cell
death by driving it ubiquitously under the control of a heat-
shock promoter (Figure 1). Embryos overexpressing TFG-1
contain significantly fewer cell corpses at the comma stage
(average of 4.1 6 1.9) than do the non-heat-shocked controls
(6.9 6 1.9, Wilcoxon rank sum, p = 1 3 1026, Figure 1C). This
decrease in cell-corpse number reflects bona fide suppression
of the apoptotic pathway, given that we observed extra surviv-
ing cells in the anterior pharynx of the resulting larvae in the
same positions as the extra survivors in mutants defective
for essential pro-apoptotic genes (Figure S1B). Thus, TFG-1
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ptotic pathway.
TFG-1 is Required to Regulate Normal Nuclear, Cell,
and Body Size
The temporal flexibility of gene inactivation by RNAi provides
an opportunity for the study of functions of essential genes
that might otherwise be masked by lethality. We found that
although elimination of TFG-1 from embryos results in lethality
prior to hatching, removal of all detectable TFG-1 by RNAi from
developing larvae that had expressed it at normal levels during
embryogenesis does not prevent growth to adulthood. How-
ever, such worms are much smaller than their wild-type coun-
terparts (Figures 3A and 3B; average length 0.73 6 0.13 mm
versus 1.34 6 0.1 mm, respectively), revealing that TFG-1 is
required during postembryonic development for the regulation
of body size. Body and organ size in animals is a function of
total cell number and individual cell size. Given that TFG-1
suppresses cell death, the reduced size of tfg-1(RNAi) worms
might be a consequence of decreased cell number as a result
of cell loss through increased apoptosis. This was not the
case: we found that the total number of DAPI-stained somatic
nuclei quantifiable in tfg-1(RNAi) worms was not significantly
different from that in wild-type (938.7 6 44.7, n = 27 and
941.3 6 43.6, n = 25, respectively; see Table 1). In contrast,
we found that the average size of both locomotory muscle cells
and epidermal cells, as well as their respective nuclei, is dra-
matically reduced in tfg-1(RNAi) adult worms compared to
wild-type (Figure 3C, Table 1, and not shown). The reduction
in cell size accounts for the reduced body size in these ani-
mals. Thus, TFG-1 influences body size primarily by controlling
the overall dimensions of individual cells.
Figure 2. Intracellular Localization of TFG-1
(A) An example of TFG-1 staining in the embryo.
(B) TFG-1 is undetectable in tfg-1(RNAi) em-
bryos.
(C) The DAPI image of the embryo in panel B.
(D–F) TFG-1 partially colocalizes with mitochon-
dria, marked with anti-COX-1 antibody. (D) An
embryo stained with anti-TFG-1 antibody. (E)
The same embryo stained with anti-COX-1 anti-
body. (F) The merged image of panels D and E.
Cell size is determined by the com-
bined action of two opposing processes,
cell growth and cell division. The number
of muscle cells in adult tfg-1(RNAi)
worms is normal (Table 1), suggesting
that TFG-1 does not affect cell division.
During postembryonic development, all but one of the lateral
epidermal (seam) cells divide during each larval stage [18].
This invariant cell-division pattern provides a useful tool to fur-
ther distinguish the influence of TFG-1 on cell division versus
growth. By examining a marker of apical junctions surrounding
epithelial cells [19], we found that seam cells undergo a similar
division pattern in tfg-1(RNAi) larvae as in wild-type, through
the molt to adulthood, confirming that TFG-1 does not alter
the number of cell divisions. In contrast, we found that seam
cells are substantially growth-inhibited in tfg-1(RNAi) worms
starting at the L3 stage, demonstrating that TFG-1 is a novel
regulator of cell growth and size. This is apparent from a
decrease in the longitudinal dimension of the seam cells
(Figure 3D). This effect is particularly dramatic by the end of
development: the body volume and volume of the diminutive
cells in tfg-1(RNAi) adults are only w30% those of wild-type
cells. Thus, TFG-1 is largely responsible for determining the
size of adult worms.
The small locomotory muscle cells in tfg-1(RNAi)worms also
contain smaller nuclei (Table 1), prompting us to examine
whether DNA content is reduced in nuclei of TFG-1-depleted
worms. A change in DNA content is often associated with an
alteration in nuclear volume and cell size: for example, the
large size of intestinal cells in worms is accompanied by in-
creased DNA ploidy of up to 32 N as a result of endoreduplica-
tion [20]. Moreover, somatic ploidy has recently been shown to
be causally linked to body size inC. elegans [21]. Nevertheless,
ploidy is only one factor underlying cell- and nuclear-size
changes: many cells of dramatically different sizes remain dip-
loid throughout life, and mutants with small body size but
with the same ploidy as wild-type have been reported [21].
We found no significant difference in the average ploidy of in-
testinal cells between dwarf tfg-1(RNAi) and control animalsTable 1. ced-4-Dependent Reduction of Cell Size in tfg-1(RNAi) Mutants
Genotype L4440(RNAi) tfg-1(RNAi)
Number of muscle cells WT 94.6 6 0.9 (n = 15) 94.2 6 1.9 (n = 15)
Muscle cell size (mm2)a WT 1709.2 6 224.9 (n = 27) 679 6 137.9 (n = 42)b
ced-4(n1162) 1322.5 6 282 (n = 50) 1254.4 6 237.5 (n = 56)
Muscle-nucleus size (mm2)a WT 79.7 6 15.8 (n = 27) 46.3 6 9.7 (n = 42)b
ced-4(n1162) 71.2 6 14.9 (n = 50) 69.1 6 14.3 (n = 56)
Total cell number WT 941.3 6 43.6 (n = 27) 938.7 6 44.7 (n = 25)
a RNAi was performed by feeding with either a control feeder (L4440, carrying an uninserted plasmid) or a tfg-1 RNAi feeder. Muscle cell size and muscle-
nucleus size were determined as the area of the largest section through the cell.
b Student’s t test, p < 0.01.
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Student’s t test, p = 0.41; Figure 4A). In addition, we observed
that epidermal nuclei, which also undergo larval endoredupli-
cation, contained a similar DNA content in tfg-1(RNAi) and
Figure 3. Cell-Size Regulation by TFG-1
(A) Adult tfg-1(RNAi) worms are much smaller than same-stage wild-type
adult worms.
(B) The body-length distribution of control (black bars) and tfg-1(RNAi) (white bars)
worms. Body-length data were pooled from three independent RNAi experiments.
(C) Muscle cells and their nuclei are smaller in adult tfg-1(RNAi) worms.
Scale bars represent 20 mm.
(D) Seam cell size during larval stages. Double asterisks indicate Student’s
t test, p < 0.01. Values are expressed as mean 6 SD.wild-type adults (7.4N 6 2.3, n = 26 versus 8.4N 6 1.6, n =
22, respectively; Student’s t test, p = 0.1). Thus, differences
in nuclear DNA content cannot explain the dramatic effect of
TFG-1 on the dimensions of nuclei and cells.
We then tested for possible genetic interactions between
TFG-1 and other cell-size-regulatory pathways. We found
that inactivation of TFG-1 in sma-3 and sma-4 mutant animals
additively reduced body size (Figure 4B), implying that the
TGF-b pathway and TFG-1 act in parallel to control cell size.
Similarly, the elongated body phenotype resulting from a muta-
tion in lon-2 is suppressed by tfg-1(RNAi) in a simple additive
relationship (Figure 4B), implying that TFG-1 and LON-2 act in-
dependently to regulate body size. This contrasts with the
strong epistatic relationship between SMA-4 and LON-2,
which are believed to act in the same pathway: sma-4(-);
lon-2 double mutants are as small as sma-4(-) single-mutant
animals [22]. Mutations that disrupt IGF- or TOR-signaling
pathways also showed no conspicuous interactions with
TFG-1 related to cell-size phenotype (not shown). Human
tumor suppressor PTEN [15], which is known to regulate cell
size, interacts with TFG; however, we found that mutations
that eliminate the function of worm PTEN, DAF-18, do not alter
the cell-size phenotype of tfg-1 (not shown). Thus, TFG-1
apparently functions in a novel pathway independent of
TGF-b and insulin signaling to control cell growth and size in
C. elegans.
CED-4 Reduces Cell Size in Mutants Lacking TFG-1
Our discovery that TFG-1 functions both to repress apoptosis
and to regulate cell size prompted us to ask whether proteins
known for their roles in apoptosis might also act in cell-size
regulation. We found that key apoptotic factors, CED-3,
CED-9, and EGL-1, do not significantly affect the diminutive
cell size in tfg-1(RNAi) animals (Figure 4C, Figure S2). In strik-
ing contrast, we observed that two strong loss-of-function
alleles of ced-4 strongly suppress the cell-size phenotypes
of adult tfg-1(RNAi) worms (Figures 5A and 5E). For example,
ced-4(n1162); tfg-1(RNAi) worms (average length 1.01 6 0.12
mm, n = 120) are similar in size to ced-4(n1162) single-mutant
animals (average length 1.14 6 0.11 mm, n = 122). Consistent
with the restored body size, we found that muscle cells in
ced-4(n1162); tfg-1(RNAi) worms are much larger than those
in tfg-1(RNAi) worms and are similar in size to muscles in
ced-4(n1162) single mutants (Figure 5B, Table 1). ced-4 mu-
tants do not appear to show reduced susceptibility to RNAi
[17]. We further confirmed the efficacy of tfg-1 RNAi in the
ced-4 mutants: TFG-1 was undetectable in extracts from both
tfg-1(RNAi) and ced-4(n1162); tfg-1(RNAi) animals (Figure 5C).
The restoration of body and cell dimensions by ced-4 muta-
tions demonstrates that CED-4 not only is necessary to acti-
vate the apoptotic program but also functions to limit cellular
dimensions. In apoptosis, the ced-4 locus possesses dual
functions as both a pro- and anti-apoptotic regulator [23]. A
similar dual role in both restricting and promoting cell growth
might also exist in CED-4-dependent cell-size regulation,
given that we observed that ced-4(-) worms have a slightly
smaller body and cell size than do wild-type worms (Figures
5A and 5D).
Caspases are the well-documented downstream effectors
of CED-4 and Apaf-1 in apoptosis, and the only proteins in C.
elegans known to possess caspase activity are CED-3 and
CSP-1 [24]. We found that removal of either one or both of
these caspases does not alter the small body size of tfg-1
(RNAi) animals (Figures 4C and 4D). For example, the average
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(A) Ploidy versus body size in diminutive tfg-1(RNAi) and control L4440(RNAi) worms.
(B) tfg-1(RNAi) and mutations of the Sma/Mab pathway show additivity in body-size reduction. Values are expressed as mean 6 SD.
(C) A ced-3(n717) mutation does not alter the small body size of tfg-1(RNAi) worms.
(D) Removal of all known caspase activity does not restore the small body size of tfg-1(RNAi) worms.body length of adult ced-3(n717); csp-1(tm917); tfg-1(RNAi)
worms (0.74 6 0.13 mm, n = 108) is virtually identical to that
of tfg-1(RNAi) worms (0.736 0.13 mm, n = 137). Also, we found
that ubiquitous high expression of baculovirus p35, a potent
pancaspase inhibitor that effectively blocks normal apoptotic
death in C. elegans [25], does not detectably alter the size of
tfg-1(RNAi) animals (not shown). These findings indicate that
although caspases are critical for CED-4-mediated apoptosis,
CED-4 apparently mediates cell-size control independently of
caspase function.
Regulation of ribosomal biogenesis and protein synthesis is
known to govern cell growth. However, the protein content of
some C. elegans mutants with altered body size, including the
larger-than-normal egl-4 mutants and diminutive sma-1 mu-
tants, does not change in proportion to their respective body
sizes. In these cases, the alteration in body size has been at-
tributed to changes in DNA content or fluid content [26]. In
contrast, we observed in tfg-1(RNAi) worms a CED-4-depen-
dent reduction in total protein content that parallels the CED-
4-dependent decrease in body and cell size (Figure 5D). The
strong correlation between body size and protein content sug-
gests that CED-4/TFG-1 probably controls cell and body size
through modulation of the protein production and accumula-
tion machinery.
CED-4 Antagonizes the Function of CREB, eIF2B,
and nucleostemin in Cell-Size Regulation
Suppression of the diminutive-cell-size phenotype of
tfg-1(RNAi) by ced-4 mutations might indicate that CED-4 an-
tagonizes normal cell-size-regulatory mechanisms, or it might
instead reflect a specific regulatory relationship between TFG-
1 and CED-4. To address this issue, we investigated whethermutants of other cell-size regulators show a CED-4-dependent
decrease in cell size. The CREB/ATF family of transcription
factors is required for cell growth and survival [27], and
CREB null mice arew30% smaller than their wild-type coun-
terparts [28]. Furthermore, cells expressing a dominant-nega-
tive form of CREB are reduced in size [29]. We found that RNAi
knockdown of the gene encoding CREB in C. elegans similarly
results in a profound decrease in body size (Figure 6A) that is
even more severe than that seen in tfg-1 mutants. The volume
of cells in these mutant adults is, remarkably, onlyw20% that
of wild-type cells. This profound cell-size phenotype was
strongly suppressed by a ced-4(n1162) mutation (Figure 6A),
underscoring the broad role of CED-4 in cell-size control.
Factors that mediate translation affect cell size; for example,
eIF2B mediates hypertrophic growth of cardiac myocytes [30].
We found that RNAi of the eIF2B-encoding gene, iftb-1, in C.
elegans results in a small-body-size phenotype, which is also
suppressed by a ced-4 mutation (Figure 6B). Thus, the action
of CED-4 in limiting cell size extends to regulation of cell
growth through a translational regulator. Nucleostemin, a nu-
cleolar GTPase enriched in proliferating stem cells and cancer
cells, has been implicated in the regulation of ribosomal as-
sembly [31]. Nucleostemin can physically interact with, and
modulate the activity of, the tumor suppressor p53. Loss of
nucleostemin results in p53-dependent apoptosis and cell
cycle arrest [32, 33], and its overexpression results in cell-
cycle arrest and formation of giant cells [34]. We found that
knock down of the expression of the worm ortholog of nucle-
ostemin results in a reduced-body-size phenotype that is
also suppressed by a ced-4(n1162) mutation (Figure 6C).
These observations demonstrate that CED-4 represses cell
growth as a result of mutations in several apparently distinct
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(A) The adult-body-length distribution of control ced-4(n1162); L4440(RNAi) (black bars) and ced-4(n1162); tfg-1(RNAi) (white bars) worms. The n1162 allele
is the reference allele that results in a stop codon at amino acid 80. Body-length data were pooled from three independent RNAi experiments.
(B) Inactivation of ced-4 restores the normal muscle-cell and nucleus size of adult tfg-1(RNAi) worms. Scale bars represent 20 mm.
(C) Western blot of extracts from wild-type and ced-4(n1162) worms without (-) and with (+) treatment of tfg-1 RNAi. tfg-(RNAi) eliminates all detectable
TFG-1.
(D) CED-4-dependent cell- and body-volume changes are proportional to total protein content. More than 30 worms per strain were used for measurement of
body volume. Total protein content is expressed as the mean 6 SD from three independent experiments.
(E) Rescue of the Sma phenotype of tfg-1(RNAi) by ced-4(n1894). The n1894 allele introduces a stop codon at amino acid 401, resulting in a truncated
protein.pathways, revealing that it acts broadly to regulate cell and
body size.
Discussion
Human TFG is involved in several different cancer types; how-
ever, the mechanism of its action in tumorigenesis is unclear.
We have found that C. elegans TFG-1 acts as both a novel apo-
ptotic suppressor and an activator of cell growth. These obser-
vations help to illuminate the role of human TFG in cancer: the in-
appropriate activity of oncogenic forms of TFG-1 might promote
tumor development by inhibiting the normal cell-death program,
which prevents tumor development, while also activating the
cell-growth-regulatory machinery. In both of these processes,
TFG-1 appears to act antagonistically with CED-4, which isessential for activation of the apoptotic program and for the
dramatic reduction of the size of cells when TFG-1 is absent.
CED-4 and its mammalian ortholog, Apaf-1, have been well
studied for their critical roles in apoptotic regulation. Both
act as adaptor proteins that trigger the activation of down-
stream caspases, thereby executing the cell-death program.
However, several recent studies have demonstrated that
CED-4/Apaf-1 has functions in other processes in addition to
apoptosis. Apaf-1 mediates DNA-damage-induced cell-cycle
arrest at the S phase [35, 36]. This DNA-damage-checkpoint
function is conserved between human and worms: loss of
CED-4 function leads to a similar cell-cycle-arrest defect in
the animal’s germline after exposure to g or UVC irradiation
[36]. CED-4 has also been found to be required for hypoxic
and volatile anesthetic preconditioning in C. elegans [37, 38].
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(A) Inactivation of ced-4 suppresses the Sma phenotype of animals depleted for the function of the C. elegans CREB gene (F57B10.1) by RNAi.
(B) Inactivation of ced-4 suppresses the Sma phenotype of iftb-1(RNAi) animals.
(C) Inactivation of ced-4 suppresses the Sma phenotype of nst-1(RNAi) animals. Student’s t test, p < 0.01.
(D) Model for the action of TFG-1 and three other cell-size regulators with CED-4 in cell size/growth control and apoptosis.Our finding that CED-4 opposes the cell-size-regulatory ac-
tion of TFG-1 reveals a new aspect of the nonapoptotic vital
functions of CED-4. It is likely that CED-4 performs a general
role in the control of body and cell size, given that it also limits
the size of cells in animals depleted for three other cell-growth-
regulating genes. It is interesting to note that C. elegans cells
developmentally programmed to die are much smaller than
their surviving sisters at the time that they are born [39]. The
CED-4 dependence of cell-size control in the adult soma and
in cells doomed to die through the developmental program
might reflect a related process mediated by this key apoptotic
regulator. Thus, some of the cell-death-activating machinery,
particularly that involving CED-4, might actively promote this
diminutive cell size at the time that a cell has committed to
the cell-death pathway. Our results imply that CED-4 is
required in many, if not all, cells for regulation of the size of
surviving cells that never trigger the apoptotic program.
As with human TFG, CREB appears to be a proto-oncopro-
tein [40]. Both CREB and PTEN, which interacts with TFG, reg-
ulate glucose metabolism and functionally interact: for exam-
ple, PTEN suppresses cyclin D2 expression and, therefore,
cell proliferation in a CREB-dependent manner [41]. We found
that RNAi knockdown of either gene inC. elegans leads to a di-
minutive-body-size phenotype that is suppressed by inactiva-
tion of ced-4. Moreover, similar to tfg-1, RNAi knockdown of
CREB also leads to an increase in embryonic cell death
(Figure S3). These observations suggest that the cell-size-reg-
ulatory mechanisms of TFG and the CREB transcription factor
might act through related pathways.
It has been suggested that C. elegans cell size is influenced
by changes in DNA content, protein synthesis, cell cycle, and/
or metabolism [42]. We found that TFG-1/CED-4-regulated
body- and cell-size control is largely independent of nuclear
DNA content but highly correlated with total protein level.This suggests that a possible mechanism for TFG-1/CED-4
function in cell- and body-size regulation is modulation of
protein production and accumulation. In support of this notion,
we found two additional factors associated with protein syn-
thesis, eIF2B and NST-1, that show CED-4-dependent body-
size regulation.
In summary, our findings related to the function of the proto-
oncogene TFG-1 and the pro-apoptotic factor CED-4 in apo-
ptosis and cell-size regulation suggest a possible link between
these two key cellular processes (Figure 6D). That CED-4
antagonizes the action of at least four genes that function in
apparently distinct processes to regulate body and, presum-
ably, cell size indicates a prominent role of CED-4 in establish-
ing appropriate cell and body size during development.
Experimental Procedures
Cell-Corpse Counts, Total-Somatic-Cell Quantification,
and Cell-Size Measurement
For cell-corpse counts, L4 animals were fed on either tfg-1(RNAi) or unc-
22(RNAi) plates for 20 hr. Developing embryos were then collected from
both populations, and the number of cell corpses were determined with
the use of Nomarski optics as described elsewhere [43, 44]. For total-so-
matic-cell quantification, freshly hatched L1 animals were fed on either
tfg-1(RNAi) or control L4440 RNAi plates and collected at late L4 stage for
fixing with Carnoy’s solution and subsequent staining with DAPI (diamidino-
phenolindole) as described elsewhere [45]. Subsequently, DAPI-stained so-
matic nuclei were counted with the use of a fluorescent microscope. Strains
harboring GFP expression in muscle and seam cells (pmyo-3::mito::GFP
and AJM-1::GFP, respectively) were used for cell-size measurement.
Embryos were hatched and subjected to either control or tfg-1(RNAi) treat-
ment. At the indicated time points, growing animals were removed and im-
aged with an Olympus Fluoview500 confocal microscope. Cell size and
length in collected images were quantified with NIH Image J software. The
volume of the rhomboid-shaped muscle cell was estimated with the equa-
tion V = SH, in which S is the maximum cross-sectional area and H is the
height/thickness of the cell. All data are reported as mean 6 SD.
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We generated synchronized worm populations by allowing 15 gravid
hermaphrodites to lay eggs on control or tfg-1 RNAi plates for 1 hr before
removing the adults and allowing eggs to develop. Three-day-old adults
that developed from these eggs were photographed on a dissecting scope
and analyzed with NIH Image J software. Body volume was calculated, with
the assumption that the worm is cylindrical, with the equation V = p(D/2)2L,
in which D is the body width across the vulva and L is the longitudinal body
length. Ploidy was measured as described elsewhere [21]. Images of nuclei
were analyzed with NIH Image J software.
Analysis of Protein Contents and Western Blots
Total protein content of 3-day-old adult animals was measured as de-
scribed elsewhere [26]. Populations of control L4440 RNAi- or tfg-1(RNAi)-
treated mixed-stage animals were collected and lysed in sodium dodecyl
sulfate (SDS) sample buffer (50 mM Tris-HCl [pH 6.8], 10% glycerol, 2%
SDS, 0.5% b-mercaptoethanol, 0.04% Bromphenol Blue). Samples were
separated by 10% SDS-polyacrylamide gel electrophoresis and transferred
to nitrocellulose membranes. Blots were probed with antibodies against
TFG-1 for the endogenous TFG-1 level in control or tfg-1(RNAi)-treated
worms. Anti-actin blots were used as an internal loading control.
Supplemental Data
Supplemental data include supplemental experimental procedures, three
figures, and one table and can be found with this article online at http://
www.current-biology.com/cgi/content/full/18/14/1025/DC1/.
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